Immunic gets rights to Daiichi's IBD candidates

Daiichi Sankyo Co. Ltd. (Tokyo:4568) granted Immunic AG (Martinsried, Germany) exclusive, worldwide rights to a group of inflammatory bowel disease candidates against an undisclosed target. Immunic said animal studies suggest the target could be disease modifying. The lead candidate, IMU-856, is in preclinical testing and Immunic said it plans to begin a Phase I trial in the near future. ...